Neoplasms, Multiple Primary: Clinical Trials

42 trials for Neoplasms, Multiple Primary, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

42 completed. 42 Phase 2, 12 Phase 1, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 242Completed 42
Phase 112Completed 12
Phase 33Completed 3

Follow Neoplasms, Multiple Primary: new trials by email Literature Review of Neoplasms, Multiple Primary trials Research Report on Neoplasms, Multiple Primary

Trials (filtered) newest first · largest first

All 42 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
LP352, bexicaserin - Developmental and Epileptic Encephalopathy, Dravet Syndrome
Phase 2CompletedLongboard Pharmaceuticals412022-11-082025-12-03
Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies
LP352, Placebo - Developmental and Epileptic Encephalopathy, Dravet Syndrome
Phase 1 / Phase 2CompletedLongboard Pharmaceuticals522022-03-032024-11-08
Basimglurant (NOE-101) in Children, Adolescents, and Young Adults With TSC
Basimglurant with crossover to Placebo, Placebo with crossover to Basimglurant - Tuberous Sclerosis Complex
Phase 2CompletedNoema Pharma AG612022-03-032025-06-04
Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients
Alpelisib, Metformin, Fulvestrant - Breast Cancer
Phase 2CompletedMedSIR692020-10-232025-07-29
Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants
TAVT-18 (sirolimus) - Tuberous Sclerosis Complex, Epilepsy
Phase 1 / Phase 2CompletedChildren's Hospital Medical Center, Cincinnati52020-09-082024-05-16
Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B)
Ganaxolone - Tuberous Sclerosis
Phase 2CompletedMarinus Pharmaceuticals232020-04-082023-04-04
Wild Blueberries and Cardiovascular Health in Middle-aged/Older Men and Postmenopausal Women
Blueberry Powder, Placebo Powder - Hypertension, Aging
Phase 1 / Phase 2CompletedColorado State University602020-01-012026-10-30
Sirolimus for Cowden Syndrome With Colon Polyposis
Sirolimus - PTEN Gene Mutation, PTEN Hamartoma Tumor Syndrome
Phase 2CompletedOhio State University52019-09-162025-06-10
Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex
rapamycin, placebo - Facial Angiofibroma, Tuberous Sclerosis
Phase 2 / Phase 3CompletedDermatology Specialties Limited Partnership1072019-07-282023-09-08
Study of Daily Application of Nestorone® (NES) and Testosterone (T) Combination Gel for Male Contraception
Nestorone + Testosterone Combination Gel - Healthy, Men
Phase 2CompletedPremier Research4202018-10-252025-02-18
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies
TAK-935, Placebo - Epilepsy, Dravet Syndrome
Phase 2CompletedTakeda1412018-08-082026-09-14
Study of Spermatogenesis Suppression With DMAU Alone or With LNG Versus Placebo Alone in Normal Men
Dimethandrolone-Undecanoate, Levonorgestrel 0.03 MG, Placebo oral capsule - Healthy, Men
Phase 2CompletedPremier Research922018-04-162025-10-30
RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome
RAD001, Placebo - PTEN Gene Mutation, PTEN Hamartoma Tumor Syndrome
Phase 1 / Phase 2CompletedBoston Children's Hospital462017-06-122025-02-17
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
pralsetinib (BLU-667) - RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer
Phase 1 / Phase 2CompletedHoffmann-La Roche5902017-03-172025-05-31
Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex
Early Vigabatrin, Delayed Vigabatrin (Placebo) - Tuberous Sclerosis Complex
Phase 2CompletedMartina Bebin842016-12-012024-08-19
Effect of PROGRESSive Training and Teststerone in Older Frail Men
testosterone, Progressive muscle training - Muscle Weakness
Phase 2 / Phase 3CompletedUniversity Hospital, Gentofte, Copenhagen1922016-11-012024-05-29
Everolimus for Cancer With TSC1 or TSC2 Mutation
Everolimus - TSC1, TSC2
Phase 2CompletedDana-Farber Cancer Institute302014-09-012020-09-16
Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery
Computed Tomography Perfusion Imaging, Laboratory Biomarker Analysis, Ziv-Aflibercept - Multiple Endocrine Neoplasia Type 1, Pancreatic Neuroendocrine Carcinoma
Phase 2CompletedNational Cancer Institute (NCI)222014-06-182020-03-23
Safety of Simvastatin in LAM and TSC
Simvastatin, Sirolimus Oral Product, Everolimus Oral Product - Lymphangioleiomyomatosis, Tuberous Sclerosis Complex
Phase 1 / Phase 2CompletedUniversity of Pennsylvania102014-03-012020-08-25
Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation
Standard of care ADT + (HMB + arginine + glutamine), Standard of care ADT - Prostate Cancer
Phase 2CompletedMedical College of Wisconsin482014-03-012023-09-22

Showing 20 of 42. Sign in to see all of them.

Narrower conditions

Tuberous Sclerosis (20)  ·  Multiple Endocrine Neoplasia Type 1 (13)  ·  Epilepsy (7)  ·  Hamartoma Syndrome, Multiple (4)  ·  Hereditary Sensory and Autonomic Neuropathies (4)  ·  Autistic Disorder (3)  ·  Breast Neoplasms (3)  ·  CDKL5 deficiency disorder (3)  ·  Carcinoma, Medullary (3)  ·  Epilepsies, Myoclonic (3)  ·  Lennox Gastaut Syndrome (3)  ·  Lymphangioleiomyomatosis (3)  ·  Multiple Endocrine Neoplasia (3)  ·  Multiple Endocrine Neoplasia Type 2a (3)  ·  Seizures (3)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (42)  ·  Genetic Diseases, Inborn (42)  ·  Neoplastic Syndromes, Hereditary (42)  ·  Neoplasms (40)  ·  Hamartoma (24)  ·  Nervous System Diseases (23)  ·  Congenital Abnormalities (21)  ·  Heredodegenerative Disorders, Nervous System (21)  ·  Nervous System Malformations (21)  ·  Neurodegenerative Diseases (21)  ·  Malformations of Cortical Development, Group I (20)  ·  Neurocutaneous Syndromes (20)  ·  Malformations of Cortical Development (19)  ·  Neoplasms by Site (18)

Interventions

Everolimus (10)  ·  Sirolimus (9)  ·  2-chloro-4-(1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl)pyridine (1)  ·  8-(6-methoxypyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethylphenyl)-1,3-dihydroimidazo(4,5-c)quinolin-2-one (1)  ·  Alpelisib (1)  ·  Anastrozole (1)  ·  Arginine (1)  ·  Autogenic Training (1)  ·  Cytidine Triphosphate (1)  ·  Erythromycin (1)  ·  Ethanol (1)  ·  Fluorodeoxyglucose F18 (1)  ·  Fulvestrant (1)  ·  Glutamine (1)  ·  Interpersonal Psychotherapy (1)

Sponsors

Children's Hospital Medical Center, Cincinnati (6)  ·  National Cancer Institute (NCI) (5)  ·  Dana-Farber Cancer Institute (2)  ·  Longboard Pharmaceuticals (2)  ·  Premier Research (2)  ·  Astellas Pharma Inc (1)  ·  Beth Israel Deaconess Medical Center (1)  ·  Boston Children's Hospital (1)  ·  Colorado State University (1)  ·  Dermatology Specialties Limited Partnership (1)  ·  Federico II University (1)  ·  Hoffmann-La Roche (1)  ·  Hugo W. Moser Research Institute at Kennedy Krieger, Inc. (1)  ·  Marinus Pharmaceuticals (1)  ·  Martina Bebin (1)

Countries

United States (39)  ·  Spain (6)  ·  Australia (5)  ·  Italy (4)  ·  Canada (3)  ·  United Kingdom (3)  ·  China (2)  ·  Israel (2)  ·  Poland (2)  ·  Taiwan (2)  ·  Belgium (1)  ·  Chile (1)  ·  Czechia (1)  ·  Denmark (1)  ·  France (1)

Top investigators

Dennis J Dlugos, MD (2)  ·  John Bissler, MD (2)  ·  Mustafa Sahin, MD, PhD (2)  ·  Andrew Herzog, M.D., M.Sc. (1)  ·  Annamaria Colao, MD, PhD (1)  ·  Antonio Llombart (1)  ·  Arun Rajan, M.D. (1)  ·  Bhavana Konda (1)  ·  Brigitte C Widemann, M.D. (1)  ·  Christopher Gardner (1)  ·  Daniel Halperin (1)  ·  Darcy Krueger, M.D. Ph.D (1)  ·  Darcy Krueger, MD, PhD (1)

Results publications

PMID 18184959, PMID 21047224, PMID 21482669, PMID 21915260, PMID 22262746, PMID 23325902, PMID 23344409, PMID 23437092, PMID 23766359, PMID 23798472, PMID 24617713, PMID 25578927, PMID 25956795, PMID 25972901, PMID 26381530, PMID 29023494, PMID 29187393, PMID 29500160, PMID 29800048, PMID 30424962, PMID 31350329, PMID 31912454, PMID 34118197, PMID 34118198, PMID 35587487, PMID 35594551, PMID 35715405, PMID 35841234, PMID 35962206, PMID 36347310, PMID 37282666, PMID 37463422, PMID 37638552, PMID 37916501, PMID 37934000, PMID 38009200, PMID 39289825, PMID 39331837, PMID 40478255, PMID 40639400, PMID 41886723

NIH funding

P30CA016672 (2), 2016 (1), 2018 (1), 2019 (1), N01CM00039 (1), N01CM00070 (1), N01CM62202 (1), N01CM62207 (1), P01DK068055 (1), P30CA006516 (1), P30CA016058 (1), R01CA107164 (1), R21CA103486 (1), U01CA062490 (1), U01NS092595 (1)